Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Aerogen
Deal Size : $212.5 million
Deal Type : Licensing Agreement
Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...
Product Name : AeroFact
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
December 22, 2021
Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Aerogen
Deal Size : $212.5 million
Deal Type : Licensing Agreement
Lead Product(s) : AP-002
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of AP-002 in Patients With Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2019
Lead Product(s) : AP-002
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
